JP2006516280A - 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法 - Google Patents

血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法 Download PDF

Info

Publication number
JP2006516280A
JP2006516280A JP2006500735A JP2006500735A JP2006516280A JP 2006516280 A JP2006516280 A JP 2006516280A JP 2006500735 A JP2006500735 A JP 2006500735A JP 2006500735 A JP2006500735 A JP 2006500735A JP 2006516280 A JP2006516280 A JP 2006516280A
Authority
JP
Japan
Prior art keywords
sphingolipid
food
cholesterol
formula
sphingolipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006500735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516280A5 (enExample
Inventor
ニューフェンフイゼン，ウィレム，フェルディナンド
Original Assignee
ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32773655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006516280(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL1022442A external-priority patent/NL1022442C2/nl
Application filed by ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー filed Critical ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー
Publication of JP2006516280A publication Critical patent/JP2006516280A/ja
Publication of JP2006516280A5 publication Critical patent/JP2006516280A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/40—Effervescence-generating compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006500735A 2003-01-20 2004-01-20 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法 Pending JP2006516280A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL1022442A NL1022442C2 (nl) 2003-01-20 2003-01-20 Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
EP03078141 2003-10-06
PCT/NL2004/000048 WO2004064820A2 (en) 2003-01-20 2004-01-20 Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels

Publications (2)

Publication Number Publication Date
JP2006516280A true JP2006516280A (ja) 2006-06-29
JP2006516280A5 JP2006516280A5 (enExample) 2007-03-01

Family

ID=32773655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500735A Pending JP2006516280A (ja) 2003-01-20 2004-01-20 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法

Country Status (7)

Country Link
US (1) US7968529B2 (enExample)
EP (1) EP1585508B1 (enExample)
JP (1) JP2006516280A (enExample)
AT (1) ATE427106T1 (enExample)
DE (1) DE602004020316D1 (enExample)
ES (1) ES2325260T3 (enExample)
WO (1) WO2004064820A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005295994A (ja) * 2004-03-19 2005-10-27 Kao Corp 皮膚保湿用食品
US7648714B2 (en) 2004-08-05 2010-01-19 Kao Corporation Food for skin moisture retention
JP5689055B2 (ja) * 2009-05-13 2015-03-25 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
JP2016013083A (ja) * 2014-07-01 2016-01-28 花王株式会社 麺つゆ

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
DE602004020316D1 (de) 2003-01-20 2009-05-14 Tno Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
AU2005220692A1 (en) * 2004-03-16 2005-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
EP1618876A1 (en) * 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for prevention and treatment of atherosclerosis
DE102004052697A1 (de) * 2004-10-29 2006-05-04 Haehner, Thomas, Dr. Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation
EP1830829B1 (en) 2004-11-30 2012-01-04 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Sphingolipids in treatment and prevention of hepatic steatosis
JP4040069B2 (ja) * 2005-08-09 2008-01-30 株式会社ミツカングループ本社 脳機能改善用組成物
JP4040070B2 (ja) * 2005-08-22 2008-01-30 株式会社ミツカングループ本社 筋肉損傷抑制組成物
JP2008013579A (ja) * 2005-08-22 2008-01-24 Mitsukan Group Honsha:Kk 筋肉損傷抑制組成物
US20100048928A1 (en) * 2005-09-22 2010-02-25 Snow Brand Milk Products Co., Ltd Medicine, Food and Drink or Feed Containing Sphingomyelin
EP1815745A1 (en) 2006-02-03 2007-08-08 Friesland Brands B.V. Cholesterol-lowering dairy products and methods for their preparation
ES2431142T3 (es) * 2006-04-07 2013-11-25 Megmilk Snow Brand Co., Ltd. Inhibidor de acumulación de grasa para el tratamiento de síndrome metabólico
TWI589228B (zh) 2009-04-23 2017-07-01 S A Corman 降低膽固醇含量之奶產品
WO2013119857A1 (en) 2012-02-07 2013-08-15 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
EP2906576B1 (en) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
JP6232008B2 (ja) * 2015-03-19 2017-11-15 国立大学法人北海道大学 酸化抑制剤及びこれを用いた油脂含有飲食品
US20170044516A1 (en) 2015-08-11 2017-02-16 Industrial Technology Research Institute Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501849A (ja) * 1988-05-09 1992-04-02 シティ・オブ・ホープ 脂肪合成の阻止
JPH06501245A (ja) * 1990-07-30 1994-02-10 ユニバーシティー オブ マイアミ 高コレステロール血症の治療法
JP2002275072A (ja) * 2001-03-21 2002-09-25 Snow Brand Milk Prod Co Ltd 脂質代謝改善剤
JP2002537407A (ja) * 1999-02-24 2002-11-05 ジョンズ・ホプキンス・ユニバーシティ 血清コレステロールを調節するための組成物及び方法。

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492259A1 (fr) 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
JPS6344842A (ja) 1986-08-12 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
BR9106744A (pt) 1990-08-13 1993-07-20 Univ Duke Processo para induzir diferenciacao celular,preparacao farmaceutica,composicao e uso de um composto
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5232837A (en) * 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) * 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
AU7374396A (en) 1995-09-29 1997-04-17 Georgetown University Use of sphingosylphosphorylcholine as a wound-healing agent
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
EP0888458A4 (en) 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
EP1520583B1 (en) 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT cell-activating agents containing alpha-glycosylceramides
US6800661B1 (en) * 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
EP1053243B1 (en) 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
JP3581010B2 (ja) 1998-03-18 2004-10-27 雪印乳業株式会社 脂質の消化吸収機能改善剤
CA2329124A1 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
US6713057B1 (en) * 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
JP3544493B2 (ja) 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
KR100341793B1 (ko) 1999-07-02 2002-06-24 권 영 근 스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
JP2001213858A (ja) 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
JP2001158735A (ja) * 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 歯周病の予防及び改善剤
JP2001158736A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
JP2003523336A (ja) 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
AU2001255199A1 (en) 2000-03-28 2001-10-08 The Liposome Company, Inc. Ceramide derivatives and method of use
JP2002068998A (ja) 2000-08-29 2002-03-08 Meiji Milk Prod Co Ltd 経腸栄養および静脈栄養に伴う脂肪肝発生予防組成物
WO2002034062A1 (en) 2000-10-27 2002-05-02 Nv Marc Boone Method for obtaining products enriched in phospho- and sphingolipids
AU2002226919A1 (en) * 2000-11-22 2002-06-03 Kc And Aa, Inc. Portable cooler for beverage container
US6949247B2 (en) * 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
FR2820037B1 (fr) 2001-01-29 2005-12-09 Dermaconcept Jmc Composition dermatologique a usage veterinaire comprenant une base sphingoide
JP2002226394A (ja) 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
US20040241249A1 (en) * 2001-06-18 2004-12-02 Tina Sampalis Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
DE60117900D1 (de) 2001-09-05 2006-05-11 Charmzone Co Phytosphingosinderivate mit Antitumorwirkung
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
DE10217555A1 (de) 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
MXPA04011312A (es) 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
US20060166934A1 (en) 2002-08-14 2006-07-27 Tae-Yoon Kim Composition comprising phytosphingosine derivatives for apoptosis induction
DE602004020316D1 (de) 2003-01-20 2009-05-14 Tno Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
GB0301395D0 (en) 2003-01-21 2003-02-19 Univ Aston Inflammatory disorder treatment
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
KR20060015534A (ko) 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501849A (ja) * 1988-05-09 1992-04-02 シティ・オブ・ホープ 脂肪合成の阻止
JPH06501245A (ja) * 1990-07-30 1994-02-10 ユニバーシティー オブ マイアミ 高コレステロール血症の治療法
JP2002537407A (ja) * 1999-02-24 2002-11-05 ジョンズ・ホプキンス・ユニバーシティ 血清コレステロールを調節するための組成物及び方法。
JP2002275072A (ja) * 2001-03-21 2002-09-25 Snow Brand Milk Prod Co Ltd 脂質代謝改善剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J NUTR BIOCHEM, vol. 11,5, JPN6010032431, 2000, pages 244 - 249, ISSN: 0001647361 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005295994A (ja) * 2004-03-19 2005-10-27 Kao Corp 皮膚保湿用食品
US7648714B2 (en) 2004-08-05 2010-01-19 Kao Corporation Food for skin moisture retention
JP5689055B2 (ja) * 2009-05-13 2015-03-25 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
JP2016013083A (ja) * 2014-07-01 2016-01-28 花王株式会社 麺つゆ

Also Published As

Publication number Publication date
EP1585508A2 (en) 2005-10-19
US7968529B2 (en) 2011-06-28
WO2004064820A2 (en) 2004-08-05
EP1585508B1 (en) 2009-04-01
WO2004064820A3 (en) 2004-09-30
ES2325260T3 (es) 2009-08-31
US20060189575A1 (en) 2006-08-24
ATE427106T1 (de) 2009-04-15
DE602004020316D1 (de) 2009-05-14

Similar Documents

Publication Publication Date Title
EP1585508B1 (en) Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
EP2258377B1 (en) Glycerophospholipids containing omega-3 and omega-6 fatty acids
US7968112B2 (en) Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20110003772A1 (en) Use of sphingolipids in the treatment of type 2 diabetes mellitus, insulin resistance and metabolic syndrome
EP1699447B1 (en) Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite
WO2008069652A1 (en) Combinations of a sphingolipid and an hmg-coa reductase inhibitor for treating hypercholesterolemia
WO2005046580A2 (en) Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
JP3467794B2 (ja) 学習能向上剤
EP2532351B1 (en) Agent for improving motility function
EP1576894A1 (en) The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
US20080085939A1 (en) Use Of Sphingolipids For Prevention And Treatment Of Atherosclerosis
US7906488B2 (en) Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
JP2021078397A (ja) 脂質減少促進剤
Hu et al. 1-Deoxysphingolipids and Their Analogs in Foods: The Occurrence and Potential Impact on Human Health Novel Functionalities of Seafoods (SY (T8) 3)
EP1661562A1 (en) Sphingolipids in treatment and prevention of steatosis
JP5621204B2 (ja) 血管老化予防剤
JP2011184347A (ja) Ｓｒｅｂｐ１抑制剤
JP2009084244A (ja) 皮膚バリア機能改善剤等

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100915

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101111